Biblio
Export 2657 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is S [Clear All Filters]
“The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1485-97, 2016.
, “The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1485-97, 2016.
, “Apolipoprotein E Related Co-Morbidities and Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 935-48, 2016.
, “Artificial Neural Networks Link One-Carbon Metabolism to Gene-Promoter Methylation in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1517-22, 2016.
, “Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 157-68, 2016.
, “Association between Coffee Consumption and Incident Risk of Disabling Dementia in Elderly Japanese: The Ohsaki Cohort 2006 Study.”, J Alzheimers Dis, vol. 50, no. 2, pp. 491-500, 2016.
, “Association between Coffee Consumption and Incident Risk of Disabling Dementia in Elderly Japanese: The Ohsaki Cohort 2006 Study.”, J Alzheimers Dis, vol. 50, no. 2, pp. 491-500, 2016.
, “Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1181-9, 2016.
, “Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1181-9, 2016.
, “Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1181-9, 2016.
, “Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 567-76, 2016.
, “Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population.”, J Alzheimers Dis, vol. 52, no. 1, pp. 43-50, 2016.
, “Association of Physical Function with Clinical and Subclinical Brain Disease: The Framingham Offspring Study.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1597-608, 2016.
, “Association of Plasma Aβ40 Peptides, But Not Aβ42, with Coronary Artery Disease and Diabetes Mellitus.”, J Alzheimers Dis, vol. 52, no. 1, pp. 161-9, 2016.
, “Association of Plasma Aβ40 Peptides, But Not Aβ42, with Coronary Artery Disease and Diabetes Mellitus.”, J Alzheimers Dis, vol. 52, no. 1, pp. 161-9, 2016.
, “Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers.”, J Alzheimers Dis, vol. 53, no. 2, pp. 621-30, 2016.
, “Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study.”, J Alzheimers Dis, vol. 51, no. 2, pp. 451-61, 2016.
, “The Associations between a Capsaicin-Rich Diet and Blood Amyloid-β Levels and Cognitive Function.”, J Alzheimers Dis, vol. 52, no. 3, pp. 1081-8, 2016.
, “Associations between Serum Omega-3 Fatty Acid Levels and Cognitive Functions among Community-Dwelling Octogenarians in Okinawa, Japan: The KOCOA Study.”, J Alzheimers Dis, vol. 51, no. 3, pp. 857-66, 2016.
, “Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amyloid-β1-40 in Hippocampal Cells.”, J Alzheimers Dis, vol. 54, no. 1, pp. 135-48, 2016.
, “Attitudes and Perceptions of Research in Aging and Dementia in an Urban Minority Population.”, J Alzheimers Dis, vol. 53, no. 1, pp. 69-72, 2016.
, “Attitudes and Perceptions of Research in Aging and Dementia in an Urban Minority Population.”, J Alzheimers Dis, vol. 53, no. 1, pp. 69-72, 2016.
, “Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.
, “Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions.”, J Alzheimers Dis, vol. 54, no. 1, pp. 307-24, 2016.
, “Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.”, J Alzheimers Dis, vol. 53, no. 2, pp. 535-46, 2016.
,